88 related articles for article (PubMed ID: 18819523)
1. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
Myschik J; McBurney WT; Hennessy T; Rades T; Hook S
Pharmazie; 2008 Sep; 63(9):686-92. PubMed ID: 18819523
[TBL] [Abstract][Full Text] [Related]
2. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.
Myschik J; McBurney WT; Hennessy T; Phipps-Green A; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):224-32. PubMed ID: 18365884
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
Myschik J; McBurney WT; Rades T; Hook S
Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Johnston D; Bystryn JC
Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
[TBL] [Abstract][Full Text] [Related]
6. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
7. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
Rizwan SB; McBurney WT; Young K; Hanley T; Boyd BJ; Rades T; Hook S
J Control Release; 2013 Jan; 165(1):16-21. PubMed ID: 23142776
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part I: Physicochemical characterisation.
Myschik J; Eberhardt F; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):213-23. PubMed ID: 18365883
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.
White K; Rades T; Kearns P; Toth I; Hook S
Pharm Res; 2006 Jul; 23(7):1473-81. PubMed ID: 16779706
[TBL] [Abstract][Full Text] [Related]
10. Impact of implant composition of twin-screw extruded lipid implants on the release behavior.
Even MP; Bobbala S; Kooi KL; Hook S; Winter G; Engert J
Int J Pharm; 2015 Sep; 493(1-2):102-10. PubMed ID: 26188320
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
Okazaki S; Iwasaki T; Yuba E; Watarai S
J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
[TBL] [Abstract][Full Text] [Related]
12. Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.
Even MP; Bobbala S; Gibson B; Hook S; Winter G; Engert J
Eur J Pharm Biopharm; 2017 May; 114():79-87. PubMed ID: 28104440
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells.
Lipford GB; Wagner H; Heeg K
Vaccine; 1994 Jan; 12(1):73-80. PubMed ID: 8303944
[TBL] [Abstract][Full Text] [Related]
14. Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice.
Sun HX; Pan HJ
Vaccine; 2006 Mar; 24(11):1914-20. PubMed ID: 16300865
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
16. Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to Bovine Viral Diarrhoea Virus E2 protein.
Mody KT; Mahony D; Zhang J; Cavallaro AS; Zhang B; Popat A; Mahony TJ; Yu C; Mitter N
Biomaterials; 2014 Dec; 35(37):9972-9983. PubMed ID: 25239045
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
Thomsen LL; Topley P; Daly MG; Brett SJ; Tite JP
Vaccine; 2004 Apr; 22(13-14):1799-809. PubMed ID: 15068864
[TBL] [Abstract][Full Text] [Related]
18. A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum.
Xie Y; Pan H; Sun H; Li D
Vaccine; 2008 Jul; 26(31):3937-45. PubMed ID: 18547688
[TBL] [Abstract][Full Text] [Related]
19. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
Vaccine; 2016 Feb; 34(9):1162-71. PubMed ID: 26826546
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice.
Sun HX; Ye YP; Pan HJ; Pan YJ
Vaccine; 2004 Sep; 22(29-30):3882-9. PubMed ID: 15364435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
